The purpose was to evaluate as to whether administration of infliximab of 12 week interval with supplementary VSL#3 is more effective or at least of similar efficacy when compared to conventional administration of infliximab only of 8 week interval.

The purpose of our study was to evaluate if supplementation of VSL#3 can improve treatment outcome for those pediatric Crohn's patients treated with infliximab every 12 weeks.

Inclusion Criteria:

• Pediatric patients who were diagnosed with severe Crohn's disease who require infliximab treatment
• confirmed diagnostic of Crohn's disease in clinical, endoscopic and histological findings

Exclusion Criteria:

• patients who has proven to have infliximab antibody